Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
April 7, 2025Podderživaûŝaâ terapiâ v onkologii.Open Access

Management of selumetinib-associated toxicity in children with neurofibromatosis type 1 and plexiform neurofibromas

View Full Paper
Ask AI
Bookmark
Share

Authors

YDYu. V. DinikinaFederal Almazov North-West Medical Research CentreNDN. S. DekhtyarevaFederal Almazov North-West Medical Research Centre

Discussion

Loading...

Member takes

Overview

Review reports adverse event management strategies for selumetinib in pediatric neurofibromatosis type 1, highlighting approaches to prevent premature drug discontinuation.

Key Points

  • To review the toxicity profile of selumetinib in pediatric patients with neurofibromatosis type 1 and outline international clinical management guidelines for drug-related adverse events.
  • Reviewed international consensus guidelines and safety literature on selumetinib in pediatric patients with inoperable symptomatic plexiform neurofibromas.
  • Evaluated clinical management protocols targeting toxicity prevention, dose modifications, and supportive interventions.
  • Selumetinib yields an objective response rate of 68% in pediatric patients with inoperable symptomatic plexiform neurofibromas.
  • Clinically significant adverse events frequently lead to treatment interruptions or discontinuation, directly lowering therapeutic adherence and overall efficacy.
  • Implementation of standardized international prevention and symptom-management guidelines allows sustained MEK inhibitor therapy while mitigating toxicities.

Cite This Study

Dinikina et al. (2025) studied this question.

synapsesocial.com/papers/6a198542f3c200df10587d78https://doi.org/10.17650/3034-2473-2025-2-1-30-43
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Ocular Effects of MEK Inhibitor Therapy: Literature Review, Clinical Presentation, and Best Practices for Mitigation2024 · 37 citations
  2. 2Pharmacotherapy of plexiform neurofibromas in patients with neurofibromatosis type 1. Possible adverse events and their management2024 · 2 citations
  3. 3Safety and efficacy of selumetinib in pediatric and adult patients with neurofibromatosis type 1 and plexiform neurofibroma2024 · 31 citations
  4. 4Efficient analysis of adverse drug events and toxicological mechanisms of newly marketed drugs by integrating pharmacovigilance and network toxicology: selumetinib as an example2024 · 21 citations
  5. 5Incidence of Ophthalmological Complications in NF-1 Patients Treated with MEK Inhibitors2024 · 9 citations